Dermatological Therapeutics

Keratinocyte is the predominant cell type in the epidermis, responsible for producing keratin and forming the protective barrier. Understanding keratinocyte turnover is essential for selecting agents that modulate differentiation, such as retinoids or vitamin D analogues. For example, topical tretinoin accelerates keratinocyte shedding, reducing comedonal acne, but may cause irritation in sensitive skin. A challenge in using potent keratinocyte‑targeting drugs is balancing efficacy with tolerability, especially in patients with compromised barrier function.

Melanocyte resides in the basal layer of the epidermis and synthesizes melanin, which determines skin colour and protects against ultraviolet (UV) radiation. Agents that affect melanocyte activity, such as hydroquinone or azelaic acid, are employed in the treatment of hyperpigmentation disorders. Practical application requires patient education on the need for strict photoprotection, as inhibition of melanin synthesis can increase susceptibility to sun‑induced damage. A common challenge is the rebound hyperpigmentation that may occur after discontinuation of depigmenting therapy.

Epidermis is the outermost skin layer composed of stratified squamous epithelium. Its structural integrity dictates the choice of formulation: Occlusive ointments are suited for intact epidermis, whereas aqueous gels are preferred for inflamed or weeping lesions. For instance, a corticosteroid cream with a low‑to‑medium potency is often selected for mild eczema affecting the face, while a higher‑potency ointment may be required for thick plaques on the elbows. The challenge lies in matching the vehicle to the disease state without compromising drug penetration.

Dermis lies beneath the epidermis and contains collagen, elastin, blood vessels, and nerve endings. Therapeutic agents that reach the dermis, such as systemic antihistamines or biologic monoclonal antibodies, must overcome the barrier presented by the stratum corneum. Intradermal injection of corticosteroids is occasionally employed for localized inflammatory nodules, but the procedure demands aseptic technique and awareness of potential atrophy. Clinicians must also consider the dermal thickness variation across body sites when dosing topical preparations.

Stratum corneum is the outermost layer of the epidermis, composed of dead, flattened keratinocytes (corneocytes) embedded in a lipid matrix. Its primary function is barrier protection and regulation of transepidermal water loss (TEWL). The concept of percutaneous absorption is directly linked to the condition of the stratum corneum; disrupted barrier, as seen in atopic dermatitis, permits greater drug penetration and may increase systemic exposure. Formulation scientists therefore design lipophilic vehicles to enhance drug flux through this layer while preserving barrier integrity.

Barrier function refers to the skin’s ability to prevent excess water loss and block entry of irritants and pathogens. Moisturizers containing humectants (e.G., Glycerin), occlusives (e.G., Petrolatum), and emollients (e.G., Dimethicone) restore barrier function by attracting water, forming a protective film, and smoothing the intercellular lipid matrix. A practical example is the use of a ceramide‑rich cream in patients with ichthyosis to replenish deficient lipids. Challenges arise when patients are non‑compliant with regular moisturization, leading to relapse of barrier‑related conditions.

Lipophilicity describes the affinity of a molecule for lipid environments and influences its ability to traverse the stratum corneum. Highly lipophilic drugs, such as corticosteroid esters, accumulate within the lipid matrix, resulting in prolonged residence time and potentially increased local efficacy. Conversely, excessively lipophilic agents may become trapped, limiting deeper dermal penetration. Formulators often balance lipophilicity by incorporating both oil‑soluble and water‑soluble phases in an emulsion.

Hydrophilicity denotes a molecule’s affinity for aqueous environments. Hydrophilic drugs, such as certain antibiotics (e.G., Mupirocin), require a vehicle that can sustain moisture to facilitate diffusion through aqueous pores. Gel formulations, which are predominantly water‑based, are ideal for delivering hydrophilic agents to moist, exudative lesions. The challenge is maintaining drug stability in aqueous media, as hydrolysis or microbial growth may compromise product integrity.

Percutaneous absorption is the process by which a substance penetrates the skin and reaches systemic circulation or deeper tissue layers. Factors influencing absorption include molecular size (< 500 Da generally favours penetration), degree of ionization, and vehicle composition. For example, the small molecule nicotinamide penetrates efficiently and is used in oral and topical formulations for acne. Clinicians must be aware of systemic toxicity risks when high‑potency agents are applied over large surface areas, especially in pediatric patients.

Occlusion refers to the application of a barrier that prevents water loss and enhances drug penetration. Occlusive dressings, such as hydrocolloid or film dressings, are employed to increase the efficacy of topical corticosteroids in thick plaques of psoriasis. While occlusion can dramatically improve therapeutic outcomes, it also raises the risk of steroid‑induced atrophy and systemic absorption. Therefore, careful monitoring of treatment duration and skin condition is essential.

Vehicle is the formulation base that carries the active pharmaceutical ingredient (API). Common vehicles include creams, ointments, gels, lotions, solutions, and suspensions. The choice of vehicle influences drug release, stability, patient acceptability, and therapeutic outcome. For instance, a non‑comedogenic lotion may be preferred for facial acne treatment to avoid pore blockage, whereas an ointment provides a richer occlusive environment suitable for chronic hand eczema. Formulators must balance physicochemical properties of the API with patient preferences to optimise adherence.

Cream is an emulsion of oil and water, typically with a semi‑solid consistency. It is suitable for areas where a moderate degree of occlusion is desired without excessive greasiness. A medium‑potency corticosteroid cream is frequently prescribed for intertriginous dermatitis because it spreads easily and does not exacerbate maceration. However, creams may be less effective on hyperkeratotic plaques where a more occlusive ointment is indicated.

Ointment is a hydrophobic, highly occlusive preparation, often based on petrolatum or mineral oil. It maximizes drug residence time and is ideal for thick, scaly lesions such as psoriasis or lichen planus. The high occlusivity of ointments can lead to increased steroid absorption and must be accounted for when prescribing potent agents. Patient education on the greasiness and potential staining of clothing is crucial to improve compliance.

Gel is a semi‑solid, water‑based system that solidifies through polymeric networks (e.G., Carbomers). Gels provide a cooling effect and are useful for inflamed or weeping lesions where a non‑occlusive vehicle is needed. For example, a topical non‑steroidal anti‑inflammatory drug (NSAID) gel is often used for localized muscular pain. A challenge with gels is the potential for rapid drug loss due to evaporation, necessitating proper storage conditions.

Lotion is a low‑viscosity fluid, typically an oil‑in‑water emulsion, designed for easy spreading over large surface areas. Lotions are advantageous for treating extensive conditions such as atopic dermatitis, where a light, non‑greasy feel promotes adherence. However, the lower occlusivity may limit the efficacy of high‑potency corticosteroids, prompting clinicians to select a higher‑strength formulation or combine with an occlusive dressing.

Solution contains a drug dissolved in a solvent, usually water, alcohol, or a mixture. Solutions are advantageous for rapid drug delivery, especially on mucosal surfaces or hairless skin. For instance, a topical antifungal solution (e.G., Terbinafine in ethanol) can quickly penetrate the stratum corneum and achieve therapeutic concentrations. Solutions may cause irritation due to solvent properties, so formulation choice must consider patient tolerance.

Suspension involves fine particles of drug dispersed in a liquid vehicle without being dissolved. Suspensions can deliver poorly soluble drugs and offer a prolonged release profile. An example is a topical corticosteroid suspension used for chronic plaque psoriasis, where the particulate nature provides a depot effect. Stability of the suspension requires adequate surfactants to prevent aggregation, and shaking before use is often required, which may affect patient compliance.

Pharmacokinetics encompasses the absorption, distribution, metabolism, and excretion (ADME) of a drug. In dermatology, the focus is often on the absorption phase, as topical agents are designed to limit systemic exposure while achieving sufficient local concentrations. For instance, the half‑life of a topical calcineurin inhibitor (e.G., Tacrolimus) in the skin may be prolonged due to binding to intracellular proteins, allowing once‑daily dosing. Understanding pharmacokinetic parameters helps clinicians anticipate potential systemic effects, especially when treating large body surface areas.

Pharmacodynamics refers to the drug’s mechanism of action and the relationship between drug concentration and effect. Topical corticosteroids exert anti‑inflammatory effects by binding glucocorticoid receptors, leading to transcriptional repression of pro‑inflammatory cytokines. The potency of a corticosteroid is classified based on its vasoconstrictive effect in the skin, which correlates with clinical efficacy. A challenge arises when patients develop tachyphylaxis, requiring rotation to a different class or intermittent dosing schedules.

Half‑life is the time required for the concentration of a drug to decrease by 50 % in the body or tissue. For topical agents, half‑life influences dosing frequency. A short half‑life may necessitate multiple daily applications, which can reduce adherence. Conversely, a long half‑life may increase the risk of accumulation and local side effects, such as skin atrophy from chronic steroid use. Clinicians must balance these factors when prescribing.

Bioavailability describes the proportion of an administered dose that reaches the site of action in an active form. Topical bioavailability is often limited by the barrier properties of the stratum corneum. Enhancers such as propylene glycol or ethanol can increase bioavailability by disrupting lipid organization, but they may also increase irritation. Practical application includes using a penetration enhancer in a formulation for onychomycosis, where the nail plate presents an additional barrier.

Systemic vs topical distinction is critical when selecting therapy. Systemic drugs, like oral isotretinoin for severe acne, affect the entire body and carry systemic adverse effects, whereas topical agents, such as adapalene gel, act locally with minimal systemic exposure. A common challenge is determining when a disease warrants systemic therapy, which often depends on severity, extent, and response to prior topical treatment.

Adverse effects encompass undesirable reactions ranging from mild irritation to severe systemic toxicity. Topical preparations may cause irritant contact dermatitis, allergic contact dermatitis, or phototoxic reactions. For example, benzoyl peroxide can cause transient erythema and dryness, while topical retinoids may lead to peeling and increased sun sensitivity. Recognising early signs of adverse effects enables timely modification of therapy to prevent escalation.

Irritant contact dermatitis is a non‑immune mediated inflammation caused by direct chemical damage to the skin barrier. Common irritants include soaps, detergents, and certain preservatives. Practical management involves identifying and eliminating the offending agent, applying barrier‑restoring moisturizers, and, if needed, short‑course low‑potency corticosteroids. A challenge is differentiating irritant dermatitis from allergic contact dermatitis, which requires patch testing.

Allergic contact dermatitis is an immune‑mediated hypersensitivity reaction to a specific allergen, often a fragrance component or a preservative such as parabens. Diagnosis is confirmed through patch testing, and management includes avoidance of the allergen and use of anti‑inflammatory agents. The chronic nature of allergic contact dermatitis can lead to lichenification, which may necessitate longer‑duration corticosteroid therapy.

Phototoxicity occurs when a chemical agent absorbs UV light and generates reactive oxygen species, leading to skin damage. Agents such as psoralen (used in PUVA therapy) and certain tetracycline antibiotics can cause phototoxic reactions. Practical advice includes strict sun avoidance and use of broad‑spectrum sunscreen during treatment. The challenge lies in patient compliance, especially when phototoxic agents are part of systemic therapy.

Photosensitivity encompasses both phototoxic and photoallergic reactions. Photoallergic dermatitis involves a delayed hypersensitivity response to a photo‑activated compound. For instance, sulfonamide antibiotics may trigger photoallergic eruptions. Management requires discontinuation of the offending drug, protective clothing, and sunscreen. Education on recognizing early signs of photosensitivity is essential to prevent severe skin injury.

Comedogenic describes a substance that promotes the formation of comedones (blackheads and whiteheads). Ingredients such as certain oils (e.G., Coconut oil) and heavy emollients can be comedogenic, worsening acne. Non‑comedogenic formulations are formulated to avoid pore blockage, often using silicone‑based polymers. Clinicians should recommend non‑comedogenic moisturizers when prescribing acne therapy to maintain barrier function without aggravating lesions.

Non‑comedogenic indicates that a product is unlikely to cause comedone formation. Such products are critical in acne management, where barrier repair is needed but pore obstruction must be avoided. A practical example is the use of a lightweight, silicone‑based gel moisturizer after topical benzoyl peroxide treatment. Challenges include patient perception of “light” formulations, which may be mistaken for insufficient moisturization.

Anti‑inflammatory agents reduce inflammation through various mechanisms. Corticosteroids inhibit phospholipase A₂, reducing prostaglandin synthesis, while calcineurin inhibitors block T‑cell activation. NSAIDs, such as diclofenac gel, inhibit cyclooxygenase enzymes locally. Choosing the appropriate anti‑inflammatory depends on disease severity, site, and risk profile. For example, long‑term steroid use on the face may cause telangiectasia, prompting a switch to a calcineurin inhibitor.

Corticosteroid is a class of steroid hormones with potent anti‑inflammatory and immunosuppressive properties. Topical corticosteroids are classified into low, medium, high, and very high potency based on vasoconstriction assays. A low‑potency steroid such as hydrocortisone 1 % is suitable for delicate areas, while a very high‑potency agent like clobetasol propionate 0.05 % Is reserved for thick plaques. Overuse can lead to atrophy, striae, and hypothalamic‑pituitary‑adrenal (HPA) axis suppression, especially when applied over large areas or under occlusion.

Glucocorticoid refers to the active component of corticosteroid medications that binds glucocorticoid receptors, mediating anti‑inflammatory effects. Synthetic glucocorticoids vary in receptor affinity and intrinsic activity. For instance, betamethasone dipropionate has higher receptor affinity than hydrocortisone, providing greater potency. Understanding glucocorticoid potency assists clinicians in tapering regimens to minimise rebound flares.

Potency classification assists prescribers in selecting an appropriate corticosteroid strength. The classification is based on comparative vasoconstrictive response in the skin, which correlates with anti‑inflammatory efficacy. Low‑potency agents are typically used for intertriginous areas, medium potency for chronic eczema, high potency for resistant psoriasis, and very high potency for short‑term use on thick plaques. Misclassification can result in under‑treatment or excessive adverse effects.

Retinoids are vitamin A derivatives that regulate cell differentiation and proliferation. Topical retinoids, such as tretinoin, adapalene, and tazarotene, are mainstays in acne and photoaging therapy. Systemic retinoids, like isotretinoin, are employed for severe nodulocystic acne. A common challenge is the irritation associated with retinoids; gradual titration and concomitant moisturization can improve tolerability.

Retinoic acid is the active metabolite of vitamin A that binds nuclear retinoic acid receptors (RARs). Topical all‑trans retinoic acid (tretinoin) promotes epidermal turnover, reducing comedonal blockage and stimulating collagen synthesis. Its use requires patient education on the potential for erythema, peeling, and heightened sun sensitivity. Co‑application with sunscreen mitigates phototoxic risk.

Tretinoin is a first‑generation topical retinoid used for acne, photodamage, and hyperkeratosis. It is available in concentrations ranging from 0.025 % To 0.1 %. Clinical practice often starts patients on a low concentration applied every other night, increasing frequency as tolerance develops. A challenge is patient adherence due to initial irritation, which can be addressed by using a moisturizer after application.

Adapalene is a third‑generation synthetic retinoid with a more favorable irritation profile. It binds selectively to RAR‑β and RAR‑γ, providing anti‑comedogenic effects with less erythema than tretinoin. Adapalene 0.1 % Gel is an over‑the‑counter option for mild to moderate acne. It is also combined with benzoyl peroxide in fixed‑dose formulations to enhance antibacterial activity. The challenge lies in ensuring patients understand the need for continued use despite early lack of visible improvement.

Isotretinoin is an oral retinoid indicated for severe cystic acne unresponsive to conventional therapy. Its mechanisms include reducing sebaceous gland size, decreasing sebum production, and normalising keratinisation. Due to teratogenicity, isotretinoin is subject to strict pregnancy‑prevention programs, requiring two forms of contraception and monthly pregnancy testing. Monitoring liver function and lipid profiles is essential, as isotretinoin can cause hepatotoxicity and hypertriglyceridaemia. The challenges include patient compliance with contraception and managing mood‑related side effects.

Calcineurin inhibitor class includes topical tacrolimus and pimecrolimus, which inhibit T‑cell activation by blocking calcineurin phosphatase activity. They are valuable in atopic dermatitis, especially on the face and neck where corticosteroid‑induced skin thinning is a concern. A practical application is the use of tacrolimus ointment 0.1 % For chronic hand eczema refractory to steroids. The main challenge is the transient burning sensation upon application, which often resolves with continued use.

Tacrolimus is a macrolide immunomodulator available as a 0.03 % Ointment for mild disease and 0.1 % For moderate‑to‑severe cases. It has a favourable safety profile for long‑term use, lacking the atrophic effects of steroids. However, concerns about a potential increased risk of lymphoma have led to black‑box warnings, although epidemiological data do not confirm a causal relationship. Patient reassurance and regular skin examinations are part of risk mitigation.

Pimecrolimus is a more selective calcineurin inhibitor with a lower potency than tacrolimus. It is formulated as a 1 % cream, primarily indicated for mild‑to‑moderate atopic dermatitis. Its lower potency reduces the incidence of burning, making it suitable for sensitive areas such as the eyelids. A challenge is that its efficacy may be insufficient for severe disease, necessitating escalation to higher‑potency steroids or systemic agents.

Biologic therapies are large‑molecule agents derived from recombinant DNA technology that target specific immune pathways. In dermatology, biologics are pivotal for moderate‑to‑severe psoriasis, hidradenitis suppurativa, and atopic dermatitis. They include monoclonal antibodies against tumor necrosis factor‑α (TNF‑α), interleukin‑23 (IL‑23), interleukin‑17 (IL‑17), and interleukin‑4/13 (IL‑4/13). Practical considerations involve screening for latent infections, monitoring for opportunistic infections, and patient education on injection technique.

Monoclonal antibody is a laboratory‑produced protein designed to bind a specific antigen. In skin pharmacology, monoclonal antibodies such as adalimumab (anti‑TNF‑α) and secukinumab (anti‑IL‑17A) provide targeted immunosuppression. Their long half‑life permits dosing intervals ranging from weekly to monthly. Challenges include high cost, the need for cold‑chain storage, and potential immunogenicity leading to loss of efficacy over time.

TNF‑α inhibitor blocks the pro‑inflammatory cytokine tumor necrosis factor‑α, a central mediator in psoriasis and psoriatic arthritis. Etanercept, infliximab, and adalimumab are widely used agents. Screening for hepatitis B and C is mandatory before initiation, as reactivation can be life‑threatening. Injection‑site reactions and the development of antibodies against the drug are common challenges that may necessitate dose adjustment or switching agents.

IL‑4/13 blocker targets the interleukin‑4 and interleukin‑13 pathways, crucial in the Th2‑driven inflammation of atopic dermatitis. Dupilumab, an IL‑4Rα antagonist, improves skin barrier function and reduces pruritus. Practical application includes subcutaneous administration every two weeks after a loading dose. A frequent adverse effect is conjunctivitis, which requires ophthalmologic evaluation. Long‑term safety data are still accumulating, presenting a challenge for clinicians.

JAK inhibitor is a small‑molecule drug that interferes with the Janus kinase (JAK) signaling pathway, thereby modulating cytokine activity. Topical ruxolitinib 1.5 % Cream is approved for mild‑to‑moderate atopic dermatitis, while oral tofacitinib and baricitinib are used for systemic disease. The oral agents carry risks of infection, thrombosis, and lipid elevation, requiring baseline and periodic laboratory monitoring. Balancing efficacy with safety is a central challenge.

Keratolysis refers to the breakdown of keratin in the stratum corneum, facilitating desquamation. Keratolytic agents such as salicylic acid, urea, and alpha‑hydroxy acids (AHAs) are employed in acne, psoriasis, and hyperkeratotic disorders. For instance, a 20 % salicylic acid pad can soften thick plaques in psoriasis, allowing better penetration of adjunctive steroids. Over‑use may cause irritation or systemic toxicity, especially with high‑dose oral salicylates.

Keratolytic agent is a substance that promotes exfoliation by disrupting intercellular cohesion. Salicylic acid, a beta‑hydroxy acid, is lipophilic and penetrates oily follicles, making it particularly effective for comedonal acne. Urea, a humectant with keratolytic properties at concentrations >10 %, is useful in ichthyosis. Practical use requires careful concentration selection to avoid excessive irritation.

Salicylic acid is a beta‑hydroxy acid with anti‑inflammatory and keratolytic activity. It is available in concentrations ranging from 0.5 % To 30 % in various formulations, including gels, pads, and soaps. In acne therapy, a 2 % gel applied once daily reduces lesion count, while a 10 % pad used weekly can treat extensive seborrheic dermatitis. Caution is required in patients with salicylate hypersensitivity or in children due to the risk of systemic absorption.

Urea at concentrations of 10‑30 % acts as a keratolytic and hygroscopic agent, facilitating water retention in the stratum corneum. It is frequently incorporated into creams for xerosis, ichthyosis, and hyperkeratotic psoriasis. Higher concentrations may cause stinging, especially on compromised skin, necessitating gradual titration. Combination products with ceramides enhance barrier restoration while providing keratolysis.

Lactic acid is an alpha‑hydroxy acid (AHA) that promotes exfoliation and improves skin hydration by increasing intercellular cohesion. A 5‑10 % lactic acid lotion is commonly prescribed for mild hyperpigmentation and dry, scaly conditions. It can be combined with urea for synergistic keratolytic effects. Over‑use may lead to irritation and photosensitivity, requiring sunscreen use.

Glycolic acid is the smallest AHA, enabling deep penetration and robust exfoliation. It is used in chemical peels for photo‑aged skin, acne scars, and melasma. Typical concentrations for at‑home products range from 5‑10 %, while professional peels may involve 30‑70 % solutions applied under controlled conditions. The main challenges include risk of burns, post‑inflammatory hyperpigmentation, and the need for strict photoprotection.

Alpha‑hydroxy acid (AHA) is a class of water‑soluble acids that exfoliate the skin surface and improve moisture retention. AHAs are employed in anti‑aging regimens, as they stimulate collagen synthesis and reduce fine lines. Combination therapy with retinoids can enhance efficacy but also increase irritation, demanding careful scheduling (e.G., Alternating nights). Patient counseling on gradual introduction and sunscreen is essential.

Beta‑hydroxy acid (BHA) is a lipid‑soluble acid, exemplified by salicylic acid, that penetrates sebaceous follicles. BHAs are particularly effective in oily or acne‑prone skin. A common formulation is a 2 % salicylic acid serum applied once daily. The challenge is preventing over‑drying, which can trigger compensatory sebum production, thus requiring moisturization.

Moisturizer restores skin hydration by delivering water, lipids, and occlusive agents. They are categorized as humectants (e.G., Glycerin), emollients (e.G., Isopropyl myristate), and occlusives (e.G., Petrolatum). A practical regimen for atopic dermatitis involves applying a humectant‑rich cream immediately after bathing to lock in moisture. Selecting the appropriate type depends on disease severity and patient preference. Over‑use of occlusives may exacerbate folliculitis in acne‑prone individuals.

Humectant attracts water from the dermis into the epidermis, enhancing skin hydration. Glycerin, hyaluronic acid, and propylene glycol are common humectants. In a moisturizer for xerosis, a high concentration of glycerin improves skin elasticity and reduces TEWL. However, humectants can be irritating at high concentrations, especially in compromised skin, necessitating balanced formulation.

Occlusive agents form a physical barrier on the skin surface, preventing water loss. Petrolatum, mineral oil, and silicone‑based polymers are typical occlusives. In severe eczema, an occlusive ointment applied at night can dramatically improve barrier recovery. The downside is the greasy feel, which may reduce adherence, especially on the face or scalp. Patient education on the benefits versus aesthetic concerns can improve compliance.

Emollient smooths the skin surface by filling intercellular gaps with lipophilic substances. Dimethicone, lanolin, and cetyl alcohol serve as emollients. They are particularly useful in conditions with rough, scaly lesions, such as psoriasis, where they reduce scaling and improve comfort. Emollients can be combined with humectants and occlusives to create a synergistic moisturizer. A challenge is potential allergenicity of lanolin in sensitive individuals.

Barrier repair strategies aim to restore the lipid matrix and protein components of the stratum corneum. Ceramide‑containing creams mimic the natural lipid composition and have shown efficacy in atopic dermatitis and ichthyosis. For instance, a ceramide‑rich barrier repair lotion applied twice daily can reduce flare frequency. The challenge is ensuring patient use continues beyond acute flare periods to maintain long‑term barrier health.

Ceramide is a sphingolipid essential for the lamellar structure of the stratum corneum. Topical ceramide formulations replenish depleted lipids in inflammatory dermatoses. A typical concentration is 3‑5 % in a cream base, providing a barrier‑restoring effect. Compatibility with other ingredients is crucial; high‑pH environments may degrade ceramides, reducing efficacy.

Antipruritic agents alleviate itch, a common symptom in many skin diseases. Topical antihistamines (e.G., Diphenhydramine cream) provide short‑term relief, while systemic agents such as antihistamines (e.G., Cetirizine) address chronic pruritus. Emerging therapies include neurokinin‑1 receptor antagonists. Practical use includes applying a topical antipruritic after a corticosteroid to reduce rebound itch. Sedating antihistamines may impair daytime functioning, limiting their use in certain populations.

Antihistamine blocks histamine receptors, reducing vasodilation and sensory nerve activation. First‑generation agents (e.G., Diphenhydramine) are sedating, whereas second‑generation agents (e.G., Loratadine) are non‑sedating. In chronic urticaria, a daily non‑sedating antihistamine is standard, with dose escalation up to four times the usual dose if needed. Monitoring for cardiac effects (e.G., QT prolongation) is necessary with certain antihistamines.

Antifungal agents target fungal pathogens responsible for dermatophytosis, candidiasis, and onychomycosis. Topical azoles (e.G., Clotrimazole) inhibit ergosterol synthesis, while allylamines (e.G., Terbinafine) block squalene epoxidase. For tinea pedis, a 1 % clotrimazole cream applied twice daily for two weeks is effective. Systemic therapy, such as oral terbinafine for onychomycosis, requires hepatic monitoring. Resistance development and drug–drug interactions are ongoing challenges.

Azole class antifungals includes imidazoles (e.G., Ketoconazole) and triazoles (e.G., Fluconazole). They bind to the cytochrome P450 enzyme lanosterol 14α‑demethylase, disrupting cell membrane synthesis. Topical azoles are first‑line for superficial infections, while oral azoles treat deeper or refractory infections. Hepatotoxicity and inhibition of CYP450 enzymes leading to drug interactions are notable concerns.

Allylamine antifungals, such as terbinafine, act by inhibiting squalene epoxidase, causing accumulation of toxic squalene and depletion of ergosterol. They are highly effective for dermatophyte infections and onychomycosis. Oral terbinafine 250 mg daily for 12 weeks achieves cure rates >70 % in toenail infections. Monitoring liver enzymes is required due to rare hepatotoxicity. Resistance is less common than with azoles but remains a potential issue.

Acne is an inflammatory disorder of the pilosebaceous unit, characterized by comedones, papules, pustules, and nodules. Pathogenesis involves excess sebum production, follicular hyperkeratinisation, Propionibacterium acnes colonisation, and inflammation. Treatment algorithms incorporate topical retinoids, benzoyl peroxide, antibiotics, and systemic agents like isotretinoin. A key challenge is patient adherence to multi‑component regimens and managing side effects such as dryness and photosensitivity.

Benzoyl peroxide is a bactericidal agent that releases free radicals, reducing P. Acnes colonisation. It also possesses mild keratolytic activity, making it an effective component of acne combination therapy. A 2.5 % Gel applied once daily can reduce inflammatory lesions with minimal irritation. Over‑use may cause bleaching of fabrics and contact dermatitis; therefore, patient counseling on proper application and avoidance of clothing contact is important.

Clindamycin is a topical antibiotic that inhibits bacterial protein synthesis. It is commonly combined with benzoyl peroxide to minimise resistance development. A 1 % clindamycin lotion applied twice daily reduces inflammatory acne lesions. The emergence of resistant strains necessitates periodic evaluation of efficacy and possible rotation to alternative agents such as azelaic acid.

Erythromycin is another topical antibiotic used in acne management. It shares a similar mechanism to clindamycin but has a higher propensity for resistance. Combination with benzoyl peroxide is recommended to preserve activity. The practical limitation includes the potential for contact dermatitis and the need for strict adherence to prevent sub‑therapeutic dosing.

Azelaic acid is a dicarboxylic acid with antibacterial, keratolytic, and anti‑hyperpigmentation properties. It is effective for both inflammatory and non‑inflammatory acne, as well as for melasma. A 15 % gel applied twice daily can improve lesion count and reduce post‑inflammatory hyperpigmentation. Irritation is less common than with retinoids, making it suitable for sensitive skin. The main challenge is patient tolerance of the gritty texture.

Psoriasis is a chronic immune‑mediated disease characterized by hyperproliferative keratinocytes and inflammatory infiltrates, leading to well‑demarcated erythematous plaques with silvery scales. Treatment options range from topical corticosteroids and vitamin D analogues to systemic agents and biologics. The choice depends on disease severity, affected body surface area, comorbidities, and patient preference. A common challenge is balancing rapid symptom control with long‑term safety, especially when using systemic immunosuppressants.

Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, reducing DNA synthesis and immune cell proliferation. It is a first‑line systemic agent for moderate‑to‑severe psoriasis.